Cathelicidin Peptide Sheep Myeloid Antimicrobial Peptide 29 Prevents Endotoxin-induced Mortality in Rat Models of Septic Shock

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 2, 2004, Pages 187-194

  Giacometti, Andrea ^a   Cirioni, Oscar ^a   Ghiselli, Roberto ^a   Mocchegiani, Federico ^a   D'Amato, Giuseppina ^a   Circo, Raffaella ^a   Orlando, Fiorenza ^a   Skerlavaj, Barbara ^a   Silvestri, Carmela ^a   Saba, Vittorio ^a   Zanetti, Margherita ^a   Scalise, Giorgio ^a  

^a c/o Ospedale Regionale ^*

Author keywords

Cathelicidins; Cationic peptides; LPS; Septic shock; Sheep myeloid antimicrobial peptide 29

Indexed keywords

CATHELICIDIN; IMIPENEM; PEPTIDE DERIVATIVE; SHEEP MYELOID ANTIMICROBIAL PEPTIDE 29; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CECUM; CONTROLLED STUDY; ESCHERICHIA COLI; LIGATION; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RAT; SEPTIC SHOCK;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD PROTEINS; ESCHERICHIA COLI; IMIPENEM; LIMULUS TEST; LIPOPOLYSACCHARIDES; MALE; POLYMYXIN B; RATS; RATS, WISTAR; SHEEP; SHOCK, SEPTIC;

EID: 9144223625     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200307-971OC     Document Type: Article

References (43)

1. Bone RC. Pathophysiology of sepsis. Ann Intern Med 1991;115:457-469.
2. Iwagaki A, Porro M, Pollack M. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect Immun 2000;68:1655-1663.
3. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991;338:732-736.
4. Hardaway RM. A review of septic shock. Am Surg 2000;66:22-29.
5. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B for CUB-Réa Network. Current epidemiology of septic shock. Am J Respir Crit Care Med 2003;168:165-172.
6. Tobin MJ. Critical care medicine in AJRCCM 2002. Am J Respir Crit Care Med 2003;167:294-305.
7. Oberholzer AU, Steckholzer M, Kurimoto O, Trentz Ertel W. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock 2001;16:411-414.
8. Villa P, Sartor G, Angelini M, Sironi M, Conni M, Gnocchi P, Isetta AM, Grau G, Buurman W, van Tits LJH, et al. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 1995;2:549-553.
9. Wenzel RP, Pinsky MR, Ulevitch RJ, Young L. Current understanding of sepsis. Clin Infect Dis 1996;22:407-413.
10. Brun-Buisson C, Doyan F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 1995;274: 968-974.
11. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-214.
12. Prins JM, Kuijper FJ, Mevissen MLCM, Speelman P, van Deventer SJH. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995;63:2236-2242.
13. Byl B, Clevenbergh P, Kentos A, Jacobs F, Marchant A, Vincent JL, Thys JP. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol Infect Dis 2001;20:804-807.
14. Manocha S, Feinstein D, Kumar A, Kumar A. Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 2002;11:1795-1812.
15. Sharma VK, Dellinger RP. Recent developments in the treatment of sepsis. Expert Opin Investig Drugs 2003;12:139-152.
16. Kotanidou A, Xagorari A ,Bagli E, Kitsanta P, Fotsis T, Papapetropoulos A, Roussos C. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am J Respir Crit Care Med 2002;165:818-823.
17. Dinarello CA, Abraham E. Does blocking cytokines in sepsis work? Am J Respir Crit Care Med 2002;166:1156-1157.
18. Yethon JA, Whitfield C. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr Drug Targets Infect Disord 2001;1:91-106.
19. Lamping N, Dettmer R, Schröder NWJ, Pfeil D, Hallatscheck D, Burger R. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998;101:2065-2071.
20. Hancock REW. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001;1:156-164.
21. Giacometti A, Cirioni O, Greganti G, Quarta M, Scalise G. In vitro activity of membrane-active peptides against Gram-positive and Gram-negative aerobic bacteria. Antimicrob Agents Chemother 1998; 42:3320-3324.
22. Hancock REW. Peptides antibiotics. Lancet 1997;349:418-422.
23. Gough M, Hancock REW, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996;64:4922-4927.
24. Giacometti A, Cirioni O, Ghiselli R, Viticchi C, Mocchegiani F, Riva A, Saba V, Scalise G. Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit Care Med 2001;29:1666-1669.
25. Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, D'Amato G, Del Prete MS, Orlando F, Kamysz W, Lukasiak J, Saba V, et al. Administration of protegrin peptide IB-367 to prevent endotoxin-induced mortality in bile duct-ligated rats. Gut 2003;52:874-878.
26. Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002;110:823-831.
27. Gennaro R, Zanetti M. Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 2000;55: 31-49.
28. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, McCray PB Jr, Lehrer RI, Welsh MJ, Tack BF. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000;68:2748-2755.
29. Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R. Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr Pharm Des 2002;8:779-793.
30. Bagella L, Scocchi M, Zanetti M. cDNA sequences of the three sheep myeloid cathelicidins. FEBS Lett 1995;376:225-228.
31. Skerlavaj B, Benincasa M, Risso A, Zanetti M, Gennaro R. SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. FEBS Lett 1999;463:58-62.
32. Guthmiller JM, Vargas KG, Srikantha R, Schomberg LL, Weisroffel PL, McCray PB Jr, Tack BF. Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob Agents Chemother 2001;45: 3216-3219.
33. Tack BF, Sawai MV, Kearney WR, Robertson AD, Sherman MA, Wang W, Hong T, Boo LM, Wu H, Waring AJ, et al. SMAP-29 has two LPS-binding sites and a central hinge. Eur J Biochem 2002;269:1181-1189.
34. Parker SJ, Watkins PE. Experimental models of Gram-negative sepsis. Br J Surg 2000;88:22-30.
35. Saklayen MG. CAPD peritonitis: incidence, pathogens, diagnosis, and management. Med Clin North Am 1990;74:997-1010.
36. Castillo M, Toledo-Pereyra LH, Gutierrez R, Prough D, Shapiro E. Peritonitis after cecal perforation. Am Surg 1991;57:313-316.
37. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 2000;13:110-116.
38. Tracey KJ, Abraham E. From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies? Shock 1999;11:224-225.
39. Sambri V, Marangoni A, Giacani L, Gennaro R, Murgia R, Cevenini R, Cinco M. Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira, Borrelia and Treponema pallidum. J Antimicrob Chemother 2002;50:895-902.
40. Giacometti A, Cirioni O, Del Prete MS, Skerlavaj B, Circo R, Zanetti M, Scalise G. In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. J Antimicrob Chemother 2003; 51:843-847.
41. Brogden KA, Kalfa VC, Ackermann MR, Palmquist DE, McCray PB Jr, Tack BF. The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection. Antimicrob Agents Chemother 2001;45:331-334.
42. Drabick JJ, Bhattacharjee AK, Hoover DL, Siber GE, Morales VE, Young LD, Brown SL, Cross AS. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent. Antimicrob Agents Chemother 1998;42:583-588.
43. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Huber O, Ambrosetti P, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42:2966-2972.